GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Acorda Therapeutics, Inc. (ACOR) [hlAlert]

Rating:
Buy ACOR
up 25.15 %

Acorda Therapeutics, Inc. (ACOR) upgraded to Buy by Merriman

Posted on: Thursday,  Oct 15, 2009  8:25 AM ET by Merriman

Merriman rated Buy Acorda Therapeutics, Inc. (NASDAQ: ACOR) on 10/15/2009, when the stock price was $25.32. Since
then, Acorda Therapeutics, Inc. has gained 25.16% as of 01/26/2016's recent price of $31.69.
If you would have followed this Merriman's recommendation on ACOR, you would have gained 25.15% of your investment in 2294 days.

Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company's lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.

Merriman provides advanced tools for acquiring such information. These tools integrate a combination of cycles, geocosmic signatures and trend analysis patterns in assisting the serious investor in their interpretation of the various financial markets and the general economy. In today's fast paced and seemingly chaotic marketplace, you need the edge that only a broader analysis of human activity can provide.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/15/2009 8:25 AM Buy
None
25.32
as of 12/31/2009
1 Week down  -7.20 %
1 Month down  -0.45 %
3 Months down  -5.33 %
1 YTD down  -5.33 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/28/2009 8:25 AM Hold
None
23.60

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy